procurement of anti diabetic inj , drugs and consumables , inj human mixtard 30-70 , inj human mixtard 50-50 , inj insulin aspart 100iu/ml (novo rapid) pen , insulin detemir (100iu) inj , insulin humalog lispro inj (recombinant dna origin) 100iu/ml cartidge , insulin isophane/nph (70%) + human insulin/soluble insulin (30%) (mixtard 30/70 insulin) inj , insulin premixed biphasic a 40 iu per ml (30% human neutral plus 70% human isophane insulin) 10ml inj , biphasic isophane insulin 50 (human insulin 50% as soluble insiline + 50% isophane insulin suspension 100 iu/ml) mixtard 50 3ml cart , human insulin analogue aspart premix 30 per insulin/70 per insulinprotamine aspart suspension 100iu/ml (monocomponent insulin, recombinant dna origin) 3ml pfp/pfs flex penrapid acting inj 100 iu/ml (recombinant dna origin) 3ml pfs , human insulin analogue aspart premix 50 per insulin/50 per insulinprotamine aspart suspension 100iu/ml (monocomponent insulin, recombinant dna origin) 3ml pfp/pfs (novomix 50) , human insulin analogue rapid acting inj 100 iu/ml (recombinant dna origin) 3ml pfs , insulin premixed biphasic human (50% human neutral 50% human isophane insulin) 10ml inj